China teams with The Lancet to boost science sharing and alliances
This article was originally published in Clinica
The Lancet hosted its “Health System Reform in China” meeting on Monday, which took place at the Great Hall of the People in Beijing, China. The event featured a series of 19 commissioned research papers that discussed the scientific evidence underpinning China’s major health challenges; they also discussed China’s health strategies and health future. The Lancet collaborated with the World Health Organization, the China Medical Board (CMB) and scientists both within and outside of China to create the event. The collaboration is expected to be long-term to ensure an ongoing presentation to the rest of the world of China’s health system, achievements and predicaments through updates via The Lancet publication. The Lancet told Clinica that it hopes the collaboration will “foster scientific and institutional alliances” between China and the rest of the world.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.